GeneAlign PGx Genetic Testing mission is to improve patient care through providing quality lab testing services, optimal therapy, reducing traditional trial and error approaches to prescribing medication, reducing adverse drug reactions, improving the selection of drug targeting, and improving drug compliance while providing healthcare professionals with the first user-friendly reporting for genetic, toxicology and pharmacogenetic testing. We strive to not only further the clinical application of laboratory testing services through research and reporting on the forefront of this field, but aid in its implementation on the ground level bringing the safety and precision of personalized medicine to both healthcare providers and consumers.
As personalized medicines become increasingly integrated into clinical practice, providers need access to actionable genetic data at point of care. GeneAlign PGx Genetic Testing offers the first comprehensive, turnkey solution to genetic, pharmacogenetic and toxicology testing implementation through cutting edge testing abilities, customized service offerings, and industry-leading software solutions.
GeneAlign pharmacogenetic testing labs was born out of three companies who came together to offer one complete, turnkey solution for pharmacogenetic testing. PinPoint Clinical, our PGx testing reference lab, provided the foundation for our services. The reference lab is where we developed, tested, and validated our technology and processes. Our consulting services through PinPoint Partners brought together our lab testing services, technology, and team of genetic experts, to offer pharmacogenetic testing and other laboratory testing capabilities to our customers. Finally, our specialty physician workflow software called Point of Care™ created a platform where PGx testing becomes meaningful to patient care through evidence-based, protocol-driven care, actionable genetic data, and navigable decision support tools, while additionally allowing providers to collect outcomes in a practical manner to validate the efficacy of PGx testing.
Never before has one company been able to offer such a unique, customizable and low-risk solution to pharmacogenetic testing.
Jim Silliman, M.D. – President and CEO
Dr. Jim Silliman is the President and Chief Executive Officer for the Company. He has an extensive career in healthcare as a practicing physician, Medical Director, hospital and physician administrator, and business development leader. From 2004 to 2012, Jim served as the Program Medical Director of the Greenville Hospital System University Medical Center and President of the Steadman Hawkins Clinic of the Carolinas.
In the early 2000’s, Jim served as the Executive Director of the Steadman Hawkins Sports Medicine Foundation in Vail, and Senior Associate at the Steadman Hawkins Clinic where he managed every aspect of the business for one of the leading orthopedic surgery organizations in the world. During this time he also founded eMed Ventures, Inc., a venture capital firm that focused on emerging health care technologies that improved hospital and physician interaction and facility management and workflow.
Jim has more than 20 years of experience in knee and shoulder sports medicine and shoulder surgery. A magna cum laude graduate of the University of Louisville Medical School, he completed his residency in Orthopedic Surgery at the University of Texas Southwestern Medical Center and completed fellowships in Lake Tahoe, California, and Vail, Colorado. He is the former program director of the Orthopedic Program at UT Southwestern. He also served for five years as the Team Physician for the U.S. Ski Team.
Jim has served as a Chairman, Director and Advisor on numerous Boards of Directors. He is also a former member of the American Academy of Orthopedic Surgeons and the American Medical Association. Jim has given dozens of presentations in conferences and symposiums across America and has been published in a variety of peer-reviewed medical publications.
Reed Silliman, Esq. – Chief Operating Officer
Reed Silliman is the Chief Operating Officer for the Company. Reed has a broad range of experience in providing general corporate and business services. Throughout his career, he has represented public and private companies in buying and selling businesses and business segments, creating joint ventures and strategic alliances, and structuring tiered entities to meet his clients changing needs. An important segment of his practice involves the representation of physicians and physician groups in the increasingly complex business environment of a health care provider.
Thurman Ballard – Senior VP of Sales and Marketing
Thurman Ballard joins the Company as the Senior Vice President of Sales and Marketing, bringing invaluable leadership qualities and business development capabilities stemming from a broad range of experience in the medical device sales arena. Thurman brings over 15 years of experience in the medical sales, including stents with Smith & Nephew Endoscopy and Conventus Orthopaedics where he filled multiple roles in sales and marketing.
Thurman received a bachelor’s degree in Kinesiology and Exercise Science from the University of Nebraska-Omaha where he also was a member of the football team. He also holds a Master’s of Business Administration degree from the University of Virginia Darden School of Business.
Brad Worthington, M.D. – CMO
Bradley Worthington, M.D. is the Chief Medical Officer for GeneAlign and is responsible for developing protocols and outcomes involving pain management. Dr. Worthington is certified by the American Board of Anesthesiology in Critical Care Medicine, Pain Medicine, and Anesthesiology.
Dr. Worthington trained at the Hospital of the University of Pennsylvania completing an Internal Medicine Internship, Anesthesiology Residency as Chief Resident, a Cardiac Anesthesiology Fellowship and a Pediatric Anesthesia and Critical Care Fellowship at the Children’s Hospital of Philadelphia.
Dr. Worthington’s professional career began with the Anesthesia Consultants of Nashville providing anesthesia services for cardiothoracic, vascular, and neurosurgical procedures for several hospitals in the Nashville area. Dr. Worthington is also former Associate Clinical Professor, Neurology and Anesthesiology, Vanderbilt University Medical Center, where he served as the Medical Director of the Vanderbilt Center for Pain Research and Neuromagnetics.
Dr. Worthington has served as the Medical Director for several freestanding ambulatory surgery and chronic inpatient and outpatient pain facilities. Dr. Worthington joins GeneAlign after serving as the Medical Director for the first outpatient ambulatory neurosurgical center in the United States and President of Neurosurgical Anesthesiologists., providing perioperative care at the busiest freestanding neurosurgical specialty hospital in the United States. During this time Dr. Worthington and his colleagues perfected and evolved the concept and practice of “Perioperativist”, developing intellectual property, processes, and procedures allowing enhanced patient recovery, dramatic decreases in adverse drug effects, length of stay, and spectacular patient satisfaction.
Dr. Worthington currently serves as the Medical Director, Perioperative Services and Anesthesiology for Surgery and Recovery Partners. Dr Worthington recently retired as an Alternate Director, American Society of Anesthesiology and has served as the President of the Tennessee Society of Anesthesiologists twice, Past President of the Nashville Society of Anesthesiologists, and recently received the Tennessee Society of Anesthesiologists Distinguished Service Award.
Cliff Bauer – Chief Development Officer of Laboratory Services
Cliff Bauer is the CDO of Laboratory Services for the Company. In this capacity, Cliff will oversee the Lab development process for PGx and Toxicology confirmation services as well as participate in the product development, oversee reference lab protocols, policies, procedures and distributor sales and marketing efforts.
Cliff has 25 years’ experience in the Medical Device industry with market leading companies such as U. S Surgical and Johnson & Johnson as well as several pre FDA device companies. With over 10 Years as a VP of Sales and Marketing for start-up companies, Cliff has launched new medical device technologies, managed international sales and marketing groups, and developed, and implemented initial U.S launch and commercialization strategies.
Cliff is President of Bauer Medical Consulting Group which assists Medical Device companies with initial product launch strategies and assists physician groups with building ancillary services.
Most recently, Cliff is co-founder and CEO of a Pharmacogenetic Lab in Florida and is consulting with additional PGx and Toxicology lab development projects.
Michael Schock – Chief Technology Officer
Michael Schock is an experienced designer, systems architect, and team leader. Michael has a BSEE (Electrical Engineering) along with over 20 years of knowledge in software system architecture, database design, project management, and personnel management. As CTO, Michael is responsible for strategy development, system architecture, and execution of technology road maps.
Previously, Michael has designed and built systems ranging from large-scale warehouses, manufacturing execution systems, and custom software-as-a-service modules for real-time data acquisition. As a veteran of the United States Navy, Michael started his career operating Nuclear Power Plants and gaining the experience to handle challenging projects and managing a wide range of talent. This has propelled him through a variety of industries. This experience spans many industries ranging from software testing of airplane ‘black boxes’ to web-based data acquisition tools utilized by the medical industry.
As a leader, Michael is a fervent believer in mentoring of junior and mid level personnel to bring out the full potential of a development team. This philosophy, along with Michael’s commitment to creating industry standard software products with an emphasis on efficiency and scalability allows the creation of superior software products from a well trained team of software engineers.